PMID- 33320984
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 26
IP  - 3
DP  - 2021 Mar
TI  - Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in 
      Older Adults with Diffuse Large B-Cell Lymphoma.
PG  - 215-223
LID - 10.1002/onco.13641 [doi]
AB  - BACKGROUND: The management of severe adverse events (AEs) is important in safely 
      and effectively providing chemotherapy to older adults with diffuse large B-cell 
      lymphoma (DLBCL). However, reports on simple and DLBCL-specific predictive models 
      for treatment-related toxicity in elderly individuals are scarce. The aim of this 
      study was to examine the usefulness of Geriatric 8 (G8) in predicting 
      treatment-related severe AEs, nonhematological toxicity, and febrile neutropenia 
      in older adults with DLBCL in real-world practice. MATERIALS AND METHODS: We 
      conducted a multicenter, retrospective study on 398 consecutive patients with 
      DLBCL (aged >/=65 years) who received standard therapy at three centers in Japan 
      (University of Fukui Hospital, the Fukui Prefectural Hospital, and the Japanese 
      Red Cross Fukui Hospital), between 2007 and 2017. RESULT: Multivariate logistic 
      analysis demonstrated that the G8 score was an independent predictive factor for 
      severe AEs. Moreover, a logistic regression model with restricted cubic spline 
      showed a nonlinear association between the incidence of severe AEs and the G8 
      score. According to receiver operating characteristic analysis, the most 
      discriminative cutoff value of the G8 for the incidence of severe AEs was 11, 
      with an area under the curve value of 0.670. AEs occurred most often in the first 
      course of chemotherapy and decreased as the course progressed. CONCLUSION: The G8 
      score, an easy-to-use geriatric assessment tool, can be a useful prediction model 
      of treatment-related severe AEs during standard therapy in older adults with 
      DLBCL. IMPLICATIONS FOR PRACTICE: In older patients with diffuse large B-cell 
      lymphoma (DLBCL), to accurately predict the risk of severe adverse events (AEs) 
      in advance is essential for safe and effective treatment. This study demonstrated 
      that the Geriatric 8 score, a simple and established geriatric assessment tool, 
      indicated a high predictive ability for occurrence of therapy-related severe AEs 
      in elderly patients with DLBCL who were treated with standard treatment.
CI  - (c) 2020 AlphaMed Press.
FAU - Oiwa, Kana
AU  - Oiwa K
AD  - Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
AD  - Department of Hematology and Oncology, Nagoya City University, Aichi, Japan.
FAU - Fujita, Kei
AU  - Fujita K
AD  - Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
AD  - Department of Hematology, Matsunami General Hospital, Gifu, Japan.
FAU - Lee, Shin
AU  - Lee S
AUID- ORCID: 0000-0002-1984-2369
AD  - Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
AD  - Department of Hematology, Matsunami General Hospital, Gifu, Japan.
FAU - Morishita, Tetsuji
AU  - Morishita T
AD  - Department of Cardiovascular Medicine, University of Fukui, Fukui, Japan.
AD  - Department Cardiovascular Medicine, National Hospital Organization Awara 
      Hospital, Fukui, Japan.
FAU - Tsukasaki, Hikaru
AU  - Tsukasaki H
AD  - Department of Hematology, Fukui Red Cross Hospital, Fukui, Japan.
FAU - Negoro, Eiju
AU  - Negoro E
AD  - Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
FAU - Ueda, Takanori
AU  - Ueda T
AD  - Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
FAU - Yamauchi, Takahiro
AU  - Yamauchi T
AD  - Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201230
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Aged
MH  - *Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Geriatric Assessment
MH  - Humans
MH  - Japan
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Rituximab/therapeutic use
PMC - PMC7930418
OTO - NOTNLM
OT  - Diffuse large B-cell lymphoma
OT  - Elderly
OT  - Geriatric 8
OT  - Prediction
OT  - Severe adverse events
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2020/12/16 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/03/01
CRDT- 2020/12/15 17:14
PHST- 2020/04/27 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/12/15 17:14 [entrez]
PHST- 2021/03/01 00:00 [pmc-release]
AID - ONCO13641 [pii]
AID - 10.1002/onco.13641 [doi]
PST - ppublish
SO  - Oncologist. 2021 Mar;26(3):215-223. doi: 10.1002/onco.13641. Epub 2020 Dec 30.